Systemic Treatment in Sarcoidosis. Study of 377 Patients from a Single University Hospital David Martinez-Lopez – Hospital Universitario Marques de Valdecilla
9:00 AM – 11:00 AM ET
Trend of Treatment Plans, and Outcomes of Therapy in Cardiac Sarcoidosis via Analysis of Standardized Uptake Values Score and Ejection Fraction Using a Cardiac PET-CT Rabia Gill, MD – Virginia Commonwealth University
9:00 AM – 11:00 AM ET
Study of Ocular Sarcoidosis and Clusters of Clinical Associations in a Series of 383 Patients with Systemic Sarcoidosis from a Single Hospital Inigo Gonzalez-Mazon, MD – H. U. Marques de Valdecilla
9:00 AM – 11:00 AM ET
Ocular Involvement and Treatment in Sarcodosis. Study of 41 Patients of a Series of 383 Patients from a Single University Hospital David Martinez-Lopez – Hospital Universitario Marques de Valdecilla
9:00 AM – 11:00 AM ET
Relationship Between Air Quality and Sarcoidosis Inflammatory Activity Aaron Case, MD – University of Illinois at Chicago
9:00 AM – 11:00 AM ET
STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis Marcia Friedman, MD – Oregon Health and Science University
9:00 AM – 11:00 AM ET
Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis Marcia Friedman, MD – Oregon Health and Science University
9:00 AM – 11:00 AM ET
Clinical Characteristics of Sarcoidosis in Asian Population: A 14-year Single Center Retrospective Cohort Study from Thailand Patompong Ungprasert, MD, MS – Cleveland Clinic, Cleveland, OH
9:00 AM – 11:00 AM ET
Pharmaco-epidemiology of Non-infectious Ocular Inflammatory Disease in a Tertiary Academic Center Sanjeev Patil, MD – University of Vermont Medical Center
9:00 AM – 11:00 AM ET
Building LSU Uveitis Registry ( BLUR ) Study – a Review of an Academic Rheumatology Center’s Experience and Approach to Uveitis Anusha Vuppala, MD – LSUHSC Shreveport
9:00 AM – 11:00 AM ET
Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center Lara Sanchez-Bilbao, MD – Hospital Universitario Marques de Valdecilla
9:00 AM – 11:00 AM ET
Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center Lara Sanchez-Bilbao, MD – Hospital Universitario Marques de Valdecilla
9:00 AM – 11:00 AM ET
Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients. Inigo Gonzalez-Mazon, MD – H. U. Marques de Valdecilla
9:00 AM – 11:00 AM ET
Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis Gary L. Craig, MD – Arthritis Northwest
9:00 AM – 11:00 AM ET
Prospective Analysis of a Cohort of Patients with Interstitial Lung Disease Associated with Connective Tissue Disease and Their Response to Immunosuppression with Mycophenolate Mofetil and Rituximab Yan Li, MD – Mayo Clinic
9:00 AM – 11:00 AM ET
Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib Eric L. Matteson, MD, MPH – Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA
9:00 AM – 11:00 AM ET
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern Paul F. Dellaripa, MD – brigham
9:00 AM – 11:00 AM ET
Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center Belén Atienza-Mateo – Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander
9:00 AM – 11:00 AM ET
Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers Kristin M. D'Silva, MD – Massachusetts General Hospital
9:00 AM – 11:00 AM ET
Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska Joanna L. Marco, MD – Allegheny Health Network
9:00 AM – 11:00 AM ET
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD) : A Single Center Study of 47 Patients- Extension Study Ahmad Qurie, MD – LSU Health Shreveport
9:00 AM – 11:00 AM ET
Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients Jose Luis Martín-Varillas, MD – Hospital Sierrallana
9:00 AM – 11:00 AM ET
Myositis and Systemic Sclerosis Spectrum IPAF Patients Are More Likely to Respond Favorably to Immunosuppression Erin Wilfong, MD, PhD – Vanderbilt University Medical Center
